ID: ALA4747789

Max Phase: Preclinical

Molecular Formula: C18H24ClN7S

Molecular Weight: 405.96

Molecule Type: Unknown

Representations

Canonical SMILES:  Nc1nc(N2CCC3(CCC[C@H]3N)CC2)cnc1Sc1ccnc(N)c1Cl

Standard InChI:  InChI=1S/C18H24ClN7S/c19-14-11(3-7-23-15(14)21)27-17-16(22)25-13(10-24-17)26-8-5-18(6-9-26)4-1-2-12(18)20/h3,7,10,12H,1-2,4-6,8-9,20H2,(H2,21,23)(H2,22,25)/t12-/m1/s1

Standard InChI Key:  YXXCYOPEUVHPLV-GFCCVEGCSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 405.96

Molecular Weight (Monoisotopic): 405.1502

AlogP: 2.94

#Rotatable Bonds: 3

Polar Surface Area: 119.97

Molecular Species: BASE

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 10.19

CX LogP: 2.47

CX LogD: -0.13

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.71

Np Likeness Score: -0.66

References

1. LaMarche MJ,Acker M,Argintaru A,Bauer D,Boisclair J,Chan H,Chen CH,Chen YN,Chen Z,Deng Z,Dore M,Dunstan D,Fan J,Fekkes P,Firestone B,Fodor M,Garcia-Fortanet J,Fortin PD,Fridrich C,Giraldes J,Glick M,Grunenfelder D,Hao HX,Hentemann M,Ho S,Jouk A,Kang ZB,Karki R,Kato M,Keen N,Koenig R,LaBonte LR,Larrow J,Liu G,Liu S,Majumdar D,Mathieu S,Meyer MJ,Mohseni M,Ntaganda R,Palermo M,Perez L,Pu M,Ramsey T,Reilly J,Sarver P,Sellers WR,Sendzik M,Shultz MD,Slisz J,Slocum K,Smith T,Spence S,Stams T,Straub C,Tamez V,Toure BB,Towler C,Wang P,Wang H,Williams SL,Yang F,Yu B,Zhang JH,Zhu S.  (2020)  Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.,  63  (22): [PMID:32910655] [10.1021/acs.jmedchem.0c01170]

Source

Source(1):

• Scientific Literature